Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Hubbard retires

This article was originally published in The Tan Sheet

Executive Summary

Randall Lutter, PhD, has been named Associate Commissioner for Policy & Planning following the retirement of William Hubbard, FDA says March 4. Hubbard is leaving the agency after "a long, distinguished career in the federal government," which included stints at OMB and the President's Council of Economic Advisors. During his tenure at FDA, Hubbard was "a major originator" of the OTC label redesign and PDUFA. Lutter joined FDA in 2002 as chief economist in the Office of Planning; he will serve as a senior advisor to Acting Commissioner Crawford, with special attention to the "public policy implications of FDA's regulatory and administrative activities"...

Randall Lutter, PhD, has been named Associate Commissioner for Policy & Planning following the retirement of William Hubbard, FDA says March 4. Hubbard is leaving the agency after "a long, distinguished career in the federal government," which included stints at OMB and the President's Council of Economic Advisors. During his tenure at FDA, Hubbard was "a major originator" of the OTC label redesign and PDUFA. Lutter joined FDA in 2002 as chief economist in the Office of Planning; he will serve as a senior advisor to Acting Commissioner Crawford, with special attention to the "public policy implications of FDA's regulatory and administrative activities"....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel